Clinical Trial Update: IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor [Phase 1]

View source ↗

Summary

Phase 1 study of IMA401 TCER in patients with recurrent or refractory solid tumors, evaluated alone or in combination with a checkpoint inhibitor; the trial is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• IMA401 TCER

Snippet

Sponsor: Immatics Biotechnologies GmbH | Conditions: Refractory Cancer, Recurrent Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING